Abstract:Background: Distinct gut microbiome signatures are associated with response, resistance, and toxicity to immune checkpoint blockade (ICB). Fecal microbiome transplants (FMT) have validated the importance of the gut microbiome in enhancing response and overcoming resistance to immunotherapy. However, donor selection remains a key challenge for FMT. Heterogenous responses using Healthy Donors (HD) and ICB Complete Responders (CR) as FMT donors suggest donor characteristics alone do not determine response. Here, we posit that donor-recipient relationships are critical in determining clinical responses to FMT. Methods: We studied a cohort of ICB-refractory, metastatic melanoma patients treated with combined FMT and ICB (10 recipients, 2 donors). Patient gut microbiomes were profiled using whole metagenomic sequencing (WMS) of longitudinal stool collections (baseline, day 7, day 31, and day 65 post-FMT). Immune infiltration of on-treatment tumor and colon biopsies was quantified with immunohistochemistry. mTraCX, an Earth Mover's Distance-based algorithm, was used to evaluate taxonomic engraftment between donors and recipients. Bray-Curtis distance was used to measure functional similarities between donor and recipient gut microbiome. Clinical findings were validated in pre-clinical FMT experiments performed on BrafV600EPten−/− melanoma-bearing mice. Results: One-third of recipients (3/10) developed an objective response (R) to ICB following FMT. mTraCX demonstrated an association between clinical response to FMT and durable engraftment of donor microbiota at day 65 post-FMT (p=0.025). Taxonomic engraftment (mTraCX) correlated positively with functional engraftment (Bray-Curtis distance) (r=0.89, p<0.0001). Enhanced engraftment was associated with increased CD4 (r = -0.87, p=0.0045) and CD8 (r = -0.6, p=0.09) T-cell infiltration in the colon, and a trend towards increased CD8 T-cell infiltration (r = -0.5, p=0.2) in the tumor following treatment with FMT+ICB. Pre-clinical models paralleled our clinical findings as responding mice showed better donor engraftment than non-responding mice (p<0.0001 on day 4 and day 24 following FMT). Conclusions: Our data shows that donor engraftment is a favorable prognostic factor for ICB treatments combined with FMT. Future investigations will aim to develop donor-recipient matching criteria to enhance the feasibility and integration of FMTs into clinical practice. Citation Format: Manoj Chelvanambi, Ashish V. Damania, Sarah B. Johnson, Golnaz Morad, Rossana N. Lazcano, Beth A. Helmink, Lon W. Fong, Khalida Wani, Y David Seo, Elizabeth M. Park, Reed I. Ayabe, Bhavana Singh, Matthew C. Wong, Davis R. Ingram, Michael G. White, Alexander J. Lazar, Aditya K. Mishra, Nadim J. Ajami, Erez N. Baruch, Jennifer A. Wargo. Engraftment as a determinant of response in fecal microbiome transplantation interventions for immunotherapy in melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6691.

Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients

Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients

Fecal microbiota transplantation and its repercussions in patients with melanoma refractory to anti-PD-1 therapy: scope review

Fecal microbiota transplantation plus anti-PD-1 immunotherapy in advanced melanoma: a phase I trial

The Use of Fecal Microbiota Transplant in Overcoming and Modulating Resistance to Anti-PD-1 Therapy in Patients with Skin Cancer

Fecal microbiota transplantation promotes immunotherapy sensitivity in refractory gastrointestinal cancer patients: open label, single-arm, single center, phase 1 study

Efficacy of fecal microbiota transplantation in patients with anti-PD-1–resistant/refractory gastrointestinal cancers.

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients

Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial

Fecal microbiota transplantation combined with anti-PD-1 inhibitor for unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor.

Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1

Fecal microbiota transplantation improves anti-PD-1 inhibitor efficacy in unresectable or metastatic solid cancers refractory to anti-PD-1 inhibitor

The Gastrointestinal Microbiome and Immune Checkpoint Inhibitors: A Review of Human Interventional Studies Among Melanoma Patients

Gut Microbiota, Metabolome, and Body Composition Signatures of Response to Therapy in Patients with Advanced Melanoma

Abstract 6691: Engraftment as a determinant of response in fecal microbiome transplantation interventions for immunotherapy in melanoma

From poo to promise: Fecal microbiota transplants support immunotherapy re-sensitization in solid tumors

Melanoma and microbiota: Current understanding and future directions

Cancer Immunotherapy: Fecal Microbiota Transplantation Brings Light

Metagenomic and metabolomic analyses reveal synergistic effects of fecal microbiota transplantation and anti-PD-1 therapy on treating colorectal cancer

Gut microbiome affects the response to immunotherapy in non-small cell lung cancer